Telomir Pharmaceuticals Inc

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm’s initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Miami, FL.

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company", an emerging leader in age-reversal science, today announced significant findings from its copper binding studies with Telomir-1. This is a promising development as the company explores Telomir-1 for the treatment of Wilson's disease and other copper related disorders.

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth potential. MIAMI, FL / ACCESSWIRE / December 12, 2024 / Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced it has raised $1 million in equity funding through The Starwood Trust.

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

On Tuesday, Telomir Pharmaceuticals, Inc. TELO revealed preclinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing several key parameters of Type 2 diabetes mellitus.

Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?

MIAMI, FL / ACCESSWIRE / December 3, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking preclinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing several key parameters of Type 2 diabetes mellitus. The study demonstrated significant reductions in fasting plasma glucose levels to basal levels, improvements in oral glucose homeostasis, and the reversal of insulin resistance to near pre-diabetic levels.

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1

MIAMI, FL / ACCESSWIRE / November 21, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking preclinical results confirming the efficacy of Telomir-1, a compound designed to effectively turn back the biological clock and support longevity. Using advanced in vivo microfluidic technology, in collaboration with Nagi Biosciences SA, the study demonstrates significant age-reversal effects in aging model organisms treated with Telomir-1, effectively turning back the biological clock.

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

Interview to Air Sunday, September 29, 2024 at 5:30 PM EST on Fox Business Network MIAMI, FL / ACCESSWIRE / September 26, 2024 / Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company seeking to lead developments in longevity science through the treatment of age-related conditions, is proud to announce that the Telomir will be featured on Health Uncensored with Dr. Drew this Sunday, September 29, 2024 at 5:30 PM EST / 2:30 PM PT on Fox Business Network. In this episode, Telomir Pharmaceuticals' Special Advisor, Dr. Michael F.

Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday

MIAMI, FL / ACCESSWIRE / September 4, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage company seeking to lead developments in longevity science through the treatment of age-related conditions, is pleased to announce the appointment of Dr. Itzchak Angel as Chief Scientific Advisor. Dr. Angel, in collaboration with Telomir's senior management, will look to expedite the pre-clinical and clinical path of Telomir's lead product candidate, Telomir-1, a novel small molecule designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process.

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

Promising results with Telomir-1 Demonstrates Potential in Promoting Life Quality and Longevity in Senior Dogs TAMPA, FL / ACCESSWIRE / August 20, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage company seeking to lead developments in longevity science through the treatment of age-related conditions, is proud to announce that its novel small molecule, Telomir-1, was recently featured in an exclusive local ABC television news segment highlighting promising "age reversal" outcomes in two senior dogs. The use of Telomir-1 in these two dogs was observed by Telomir's special advisor Dr. Michael Roizen, the former Chief Wellness Officer of the Cleveland Clinic and a leader in age-related medicine.

Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs

Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 to promote longevity in humans and dogs through the treatment of age-related conditions, today announced the passing of Chairman of the Board and Chief Executive Officer Christopher Chapman, Jr., M.D.

Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman

TAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA's protective telomere caps as a potential treatment for age-related conditions, today announced that the Company has been added as a member of the broad-market Russell 3000® and the Russell Microcap® Indexes, effective July 1, as part of the 2024 Russell indexes reconstitution.

Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes

Drug Information Association (DIA) 2024 is the largest global, multidisciplinary event for the professionals involved in the discovery, development, and lifecycle management of pharmaceuticals, biotechnology, medical devices, and related products Drug Information Association (DIA) 2024 is the largest global, multidisciplinary event for the professionals involved in the discovery, development, and lifecycle management of pharmaceuticals, biotechnology, medical devices, and related products

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic material in chromosomes to combat aging

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

Telomir's pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase

Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases

UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Continued work with computer-aided pre-clinical testing shows Telomir-1 has the potential to extend DNA telomeres to reverse age-related conditions Continued work with computer-aided pre-clinical testing shows Telomir-1 has the potential to extend DNA telomeres to reverse age-related conditions

Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal Science

Together with its partner, Frontage Laboratories, Telomir's poster focused on pre-clinical data demonstrating Telomir-1's ability to elongate telomere caps on human stem cells, targeting age-related inflammatory conditions Together with its partner, Frontage Laboratories, Telomir's poster focused on pre-clinical data demonstrating Telomir-1's ability to elongate telomere caps on human stem cells, targeting age-related inflammatory conditions

Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference

Dr. Roizen to provide expertise on longevity and aging Research on aging involving Telomir's lead product candidate focused on  reversing age-related decline and the extension of human life BALTIMORE, March 05, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA's protective telomere caps in order to affect age reversal, today announced that Michael F. Roizen, MD, a leader in age-related medicine and an existing advisor to the Company, will be increasing his role in the coming months as a Special Advisor on Age Reversal.

Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal

BALTIMORE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA's protective telomere caps in order to affect age reversal, today announced the closing of its initial public offering of 1,000,000 shares of common stock at a public offering price of $7.00 per share. The gross proceeds to Telomir from the initial public offering were $7 million, before deducting underwriting discounts and commissions and other offering expenses. All the shares of common stock were offered by Telomir. The shares began trading on The Nasdaq Capital Market on February 9, 2024, under the ticker symbol "TELO."

Telomir Pharmaceuticals Announces Closing of Initial Public Offering

Telomir Pharmaceuticals plans to raise $7 million through an IPO to fund its development of treatments for age-related inflammatory conditions. The company's lead candidate, TELOMIR-1, has the potential to act as an Interleukin-17 inhibitor for conditions such as hemochromatosis and osteoarthritis. Given TELO's thin capitalization, high valuation expectations and early stage of development, my opinion on the IPO is to Sell [Avoid].

News for Telomir Pharmaceuticals Inc Stock (TELO)